A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

• Status: RECRUITING
• Trial end date: 2027-12-31

Summary

The purpose of this study is to evaluate the effectiveness and safety of capivasertib + fulvestrant treatment administration in patients with locally advanced (inoperable) or metastatic HR+ / HER2- breast cancer with PIK3CA/AKT1/PTEN-altered following recurrence or progression on or after endocrine therapy and CDK4/6 inhibitor.

• Phase: PHASE3

Details

• Lead Sponsor: AstraZeneca
• Collaborators: Apices Soluciones S.L.; SOLTI Breast Cancer Research Group
• Treatments: capivasertib; Fulvestrant